Continuous glucose monitoring worth $1.2 billion to Abbott
This article was originally published in Clinica
Executive Summary
Abbott Laboratories has offered $1.2bn in cash for TheraSense, a developer and marketer of glucose monitors. Although Abbott has its own MediSense range of blood glucose monitors for diabetic patients, it is keen to establish a position in the next generation of these products, which are seeing a greater focus on reduced pain and continuous measurement.